- Edoxaban tosylate
-
- $5.00
-
2026-04-10
- CAS:480449-71-6
- Min. Order: 1KG
- Purity: 99% hplc
- Supply Ability: 500TONS
- Edoxaban (tosylate)
-
-
2026-04-09
- CAS:480449-71-6
- Min. Order: 1kg Ton
- Purity: 99%+
- Supply Ability: 2 tons/month
- Edoxaban tosylate
-
-
2021-09-16
- CAS:480449-71-6
- Min. Order: 100g
- Purity: 99%
- Supply Ability: 500KG
|
| | Edoxaban tosylate Basic information |
| Product Name: | Edoxaban tosylate | | Synonyms: | Edoxaban TsOH;Edoxaban (TsOH salt);Edoxaban tosylate;Edoxaban tosylate
(DU-176b);C24H30ClN7O4S.C7H7HSO3 Edoxaban (TsOH salt) 480449-71-6;9H-FLUORENE-2,11-DICARBOXYLICACID;Edoxaban p-Toluenesulfonate;N'-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide | | CAS: | 480449-71-6 | | MF: | C24H30ClN7O4S.C7H8O3S | | MW: | 720.26 | | EINECS: | 1592732-453-0 | | Product Categories: | | | Mol File: | 480449-71-6.mol |  |
| | Edoxaban tosylate Chemical Properties |
| storage temp. | Store at -20°C | | solubility | 25℃: DMSO | | form | Powder | | color | White to off-white | | InChIKey | ZLFZITWZOYXXAW-BUZWFPPCNA-N | | SMILES | S(C1C=CC(C)=CC=1)(O)(=O)=O.N([C@@H]1C[C@@H](C(=O)N(C)C)CC[C@@H]1NC(=O)C(=O)NC1N=CC(Cl)=CC=1)C(C1SC2CN(C)CCC=2N=1)=O |&1:12,14,22,r| |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | Edoxaban tosylate Usage And Synthesis |
| Uses | Edoxaban tosylate (Lixiana; Daiichi Sankyo, Tokyo, Japan), known as DU-176b in clinical trials, is a novel oral direct factor Xa inhibitor. Edoxaban has good bioavailability with maximum plasma concentration achieved 1–2 h after ingestion and plasma half-life of 8–10 h. Edoxaban is a novel anticoagulant (NOAC) indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis and pulmonary embolism.
| | Definition | ChEBI: An organosulfonate salt obtained by combining equimolar amounts of edoxaban and 4-toluenesulfonic acid. Used (in the form of its monohydrate) for the treatment of deep vein thrombosis and pulmonary embolism. | | in vivo | Edoxaban tosylate (0.5, 2.5 and 12.5 mg/kg; p.o.; once) significantly and dose-dependently reduces the thrombus formation and prolongs PT[1]. | Animal Model: | Male Slc: Wistar rats (210-240 g); Male New Zealand White rabbits(2.5-3.5 kg) (Both are venous stasis thrombosis model)[1]. | | Dosage: | 0.5, 2.5 and 12.5 mg/kg | | Administration: | Oral administration; once | | Result: | Inhibited exogenous FXa activity.
Antithrombotic. |
|
| | Edoxaban tosylate Preparation Products And Raw materials |
|